公司資料
Medpace 股價、新聞與催化劑
- 股票代碼:
- MEDP
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
597.12 USD (+3.22%)
收盤價
最後更新: 2026年8月17日
12.7B USD
市值
股價為何變動
As of Aug 17, 2026, MEDP closed up 3.22% at $597.12. No new same-company headline was identified in the current news window.
公司概覽
Full-Service Clinical Research
Medpace is a global contract research organization providing Phase 1 through Phase 4 clinical-development services to biotechnology, pharmaceutical and medical-device companies.
Therapeutic and Scientific Expertise
The company uses physician leadership and therapeutic-area specialists to support protocol design, regulatory planning, trial execution and data interpretation. This scientifically driven model is particularly relevant for emerging biotechnology sponsors with limited internal development infrastructure.
Integrated Trial Operations
Medpace offers project management, clinical monitoring, data management, biostatistics, medical writing, safety and laboratory services through an integrated operating model. Its global network allows sponsors to run multinational studies with a single primary CRO.
未來催化劑
- Medpace’s watchlist is backlog conversion, study-start momentum, and how biotech funding trends affect CRO demand. That readout matters because it decides whether the asset is ready for a larger and more expensive development step. If the data come in cleanly, the market tends to give the broader platform behind the program more credit.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。